CMBC CAPITAL (01141): Li Ming no longer serves as the General Manager.
Minyin Capital (01141) announced that Mr. Li Ming recently informed the company that, due to an internal job transfer within the China Minsheng Banking Corporation Limited (the indirect controlling shareholder of the company), he will not seek re-election at the upcoming annual general meeting of shareholders and will step down as an executive director of the company at the end of the meeting. After his resignation, Mr. Li will no longer serve as the company's general manager, nor as a member of the executive committee, risk management and internal control committee, and development strategy committee of the company.
CMBC CAPITAL (01141) announced that Mr. Li Ming recently informed the company that, due to an internal job transfer within the China Minsheng Banking Corp., Ltd. (an indirect controlling shareholder of the company) group, he will not seek re-election at the upcoming annual general meeting of shareholders and will retire as an executive director of the company at the end of the annual general meeting. After his retirement, Mr. Li will no longer serve as the CEO of the company, and will also cease to be a member of the company's executive committee, risk management and internal control committee, and development strategy committee.
Related Articles
SIWI SCI & TECH (01202) will distribute a final dividend of HK$0.115 per 10 shares on July 31.
SMART-CORE(02166) plans to discount about 15.01% to allocate up to 97.7362 million shares, raising approximately HK$291 million net.
AbbVie is making a bold $10.9 billion bet on the next "drug king"! AbbVie is acquiring Apogee with a 49% premium, aiming for Sanofi's Dupixent.
SIWI SCI & TECH (01202) will distribute a final dividend of HK$0.115 per 10 shares on July 31.
SMART-CORE(02166) plans to discount about 15.01% to allocate up to 97.7362 million shares, raising approximately HK$291 million net.
AbbVie is making a bold $10.9 billion bet on the next "drug king"! AbbVie is acquiring Apogee with a 49% premium, aiming for Sanofi's Dupixent.
RECOMMEND
